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Letter to the EditorDear Editor,
The successful inclusion of succinylacetone as a marker of
tyrosinemia type I in Tuscany newborn screening program
Tyrosinemia type I (MIM 276700) is an autosomal recessive
disorder due to the deficiency of fumarylacetoacetic hydrolase
(EC 3.7.1.2), the last enzyme in the tyrosine metabolism. This
condition, if not treated, is characterized by severe liver failure
and renal and neurological involvement.1 The availability of
an effective treatment has increased the need to improve early
detection and has made this disease an eligible candidate forFigure 1. Panel 1: the patient affected by tyrosinemia type I iden
the normal ranges (1a) whereas high levels of SA are detected (1b
the normal ranges.newborn screening by flow injection analysis tandem mass
spectrometry (FIA-MS/MS).2 Up to now, tyrosine has been
the commonmarker for tyrosinemia type I, causingmany false
positive and false negative results.3,4 Indeed a great number of
affected infants have normal tyrosine levels at the time of the
routine heel-stick for newborn screening. To better detect
tyrosinemia type I through newborn screening, succinylace-
tone (SA), the primary diagnostic marker for tyrosinemia type
I, has been recently introduced into the panel of the
metabolites tested.5,6
Since January 2007, 87 700 newborns from Tuscany have
been screened using FIA-MS/MS by a modified method
including SA, as reported by laMarca.5 During this period, we
diagnosed an infant with tyrosinemia type I through newborn
screening. The patient, a female, is the second child of first-
cousin Turkish parents. Their first son, born after three
consecutive miscarriages, is healthy. She was born at term
(Apgar score 9I to 10V) with a weight of 3150g after an
uneventful pregnancy and delivery. Neonatal screening
revealed a SA value of 7.6mmol/L (n.v. <2) and normal
tyrosine values (126mmol/L; n.v. <250) (Fig. 1). She was
admitted to hospital and diagnosis of tyrosinemia type I was
I: 10.1002/rcm.4289tified through newborn screening. Tyrosine levels are within
). Panel 2: control with tyrosine (2a) and SA (2b) levels within
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3892 Letter to the Editorconfirmed on a second dried blood spot (DBS) and urine. On
the fifth day of life the child was in good clinical condition
and no clinical signs of hepatopathy were noted. Treatment
with 2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione
(NTBC) (1mg/kg/day) and a low protein intakewere started.
As reported in our previous work,5 SA was coextracted
with acylcarnitines and amino acids by using a mixture of
hydrazine hydrate (1mmol/L) in water and methanol.
Modifications of the routinely newborn screening procedure
previously used and described by us7 were limited to
extraction time extended to 25min instead of 20min and to
extraction temperature increased up to 378C instead of room
temperature. The derivatization phase was not modified.
Several hydrazine concentrations (up to 24mmol/L) were
tested. As the concentration of hydrazine becomes higher,
ionization efficiency decreases and hydrolysis and interfer-
ing components increase. The choice to use hydrazine
hydrate instead of the commercially available hemisulfate,
sulfate or dihydrochloride salts was made to avoid
production even only of a small amount of sulfuric acid
and hydrochloric acid. Moreover, 1mmol/L concentration of
hydrazine was used because it could extract succinylacetone
without any significant interferences with the analyticalFigure 2. Confirmation test by using a HPLC method. Extracted
standard (IS) is detected (a); extracted ion chromatogram of the aff
to SA is well depicted under the IS peak.
Copyright # 2009 John Wiley & Sons, Ltd.performance and with the quantitative assay. The final pH of
the solution is 4.4 and is not strong enough to cause acid
hydrolysis of ester groups. Hydrazine hydrate solution does
not modify acylcarnitine and amino acid concentrations, as
demonstrated by la Marca.5 The detection of butylated SA
and 13C4-SA (internal standard) hydrazones was performed
by two MRM transitions m/z 211!137 and m/z 215!141,
respectively.One SA-spikedDBS (5mmol/L) is run every day
to ensure that the SA extraction procedure has come to
completion. In this patient, the diagnosis of tyrosinemia type
I was confirmed by a modified high-performance liquid
chromatography (HPLC) method8 on DBS and urine speci-
mens. The modification concerned the use of hydrazine
hydrate solution (1mmol/L) instead of dansylhydrazine
solution (2.5mmol/L) during the first derivatization step.
The resulting SA level was 10.0mmol/L on the second DBS
(v.n. <2) (Fig. 2) and 92.3mmol/mmol of creatinine (v.n.
0.006–0.14) in urine.
This case demonstrated that the inclusion of SA in
newborn screening programs improves the effectiveness to
identify infants affected by tyrosinemia type I. A variety of
sample preparation methods are reported to determinate SA
on DBS.9 As far as we know, the elevation of bloodion chromatogram of a normal DBS whereas only internal
ected newborn DBS at recall (b). A clear signal corresponding
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Letter to the Editor 3893succinylacetone detected by newborn screening has been
described only once prior to this report in two newborns, and
was identified on residual spots, after extraction of acylcar-
nitines and amino acids, by separate runs.10 Our method
allows SA to be extracted simultaneously with acylcarnitines
and amino acids. The application of this method, which has
proven to be accurate and reliable, offers many advantages
including time saving and no additional costs. No second tier
test is needed. We believe that the SA determination should
be performed in all newborn screening programs.
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